175 related articles for article (PubMed ID: 35495113)
1. Classification of lung adenocarcinoma based on stemness scores in bulk and single cell transcriptomes.
Liu Q; Lei J; Zhang X; Wang X
Comput Struct Biotechnol J; 2022; 20():1691-1701. PubMed ID: 35495113
[TBL] [Abstract][Full Text] [Related]
2. Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma.
Liu Q; Nie R; Li M; Li L; Zhou H; Lu H; Wang X
Comput Struct Biotechnol J; 2021; 19():4472-4485. PubMed ID: 34471493
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer.
Lin BB; Lei HQ; Xiong HY; Fu X; Shi F; Yang XW; Yang YF; Liao GL; Feng YP; Jiang DG; Pang J
Comput Struct Biotechnol J; 2021; 19():4941-4953. PubMed ID: 34527198
[TBL] [Abstract][Full Text] [Related]
4. Identification of prostate cancer subtypes based on immune signature scores in bulk and single-cell transcriptomes.
Chen C; Luo J; Wang X
Med Oncol; 2022 Jun; 39(9):123. PubMed ID: 35716212
[TBL] [Abstract][Full Text] [Related]
5. Stratification of glioma based on stemness scores in bulk and single-cell transcriptomes.
Abdelrahman Z; Abdelatty A; Luo J; McKnight AJ; Wang X
Comput Biol Med; 2024 Jun; 175():108304. PubMed ID: 38663352
[TBL] [Abstract][Full Text] [Related]
6. Proteomics-based clustering of lung adenocarcinoma identifies three subtypes with significantly different clinical and molecular features.
Long R; Abulimiti N; Wang X
Clin Transl Oncol; 2024 Feb; 26(2):538-548. PubMed ID: 37603150
[TBL] [Abstract][Full Text] [Related]
7. Stromal Signals Dominate Gene Expression Signature Scores That Aim to Describe Cancer Cell-intrinsic Stemness or Mesenchymality Characteristics.
Kreis J; Aybey B; Geist F; Brors B; Staub E
Cancer Res Commun; 2024 Feb; 4(2):516-529. PubMed ID: 38349551
[TBL] [Abstract][Full Text] [Related]
8. Identification of Breast Cancer Immune Subtypes by Analyzing Bulk Tumor and Single Cell Transcriptomes.
Yao J; Li S; Wang X
Front Cell Dev Biol; 2021; 9():781848. PubMed ID: 35047498
[No Abstract] [Full Text] [Related]
9. Molecular classification of human papillomavirus-positive cervical cancers based on immune signature enrichment.
Song G; Luo J; Zou S; Lou F; Zhang T; Zhu X; Yang J; Wang X
Front Public Health; 2022; 10():979933. PubMed ID: 36203656
[TBL] [Abstract][Full Text] [Related]
10. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
11. The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression.
Zhang Z; Li L; Li M; Wang X
Comput Struct Biotechnol J; 2020; 18():2438-2444. PubMed ID: 32905022
[TBL] [Abstract][Full Text] [Related]
12. Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma.
Zhou X; Xu R; Lu T; Xu R; Wang C; Peng B; Chang X; Shen Z; Wang K; Shi J; Zhao J; Zhang LY
Aging (Albany NY); 2023 Aug; 15(16):8090-8112. PubMed ID: 37578930
[TBL] [Abstract][Full Text] [Related]
13. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
[TBL] [Abstract][Full Text] [Related]
14. A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma.
Ouyang W; Jiang Y; Bu S; Tang T; Huang L; Chen M; Tan Y; Ou Q; Mao L; Mai Y; Yao H; Yu Y; Lin X
Front Cell Dev Biol; 2021; 9():758777. PubMed ID: 35141229
[No Abstract] [Full Text] [Related]
15. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
Wang Z; Wang C; Lin S; Yu X
Front Oncol; 2021; 11():725292. PubMed ID: 34513703
[TBL] [Abstract][Full Text] [Related]
16. Subtyping of head and neck squamous cell cancers based on immune signatures.
Song D; Lyu H; Feng Q; Luo J; Li L; Wang X
Int Immunopharmacol; 2021 Oct; 99():108007. PubMed ID: 34332341
[TBL] [Abstract][Full Text] [Related]
17. Investigating the Clinico-Molecular and Immunological Evolution of Lung Adenocarcinoma Using Pseudotime Analysis.
Lee H; Choi H
Front Oncol; 2022; 12():828505. PubMed ID: 35311086
[TBL] [Abstract][Full Text] [Related]
18. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
20. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
